로그인 회원가입
icon_bulk_order대량 주문 Acrobiosystems for English
0
장바구니가 비어 있습니다
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: > Cell > ASGR1 > CHEK-ATP080

HEK293/Human ASGR1 Stable Cell Line

  1. Genetically modified cell lines best reflect MOA (Mechanism of Action)
  2. Higher activity and larger assay window for robust and reproducible cell-based bioassay
  3. Comprehensive application data to support assay development and validation
  4. Full tracible record, stringent quality control and validated cell passage stability
  5. Parental cell line legally obtained from internationally recognized cell resource bank and commercially licensed
  6. Global commercial license assistance whenever regulatory filing is required
  • Description
    HEK293/Human ASGR1 Stable Cell Line
  • Application

    Binding assay by FACS and cell based ELISA.

  • Growth Properties
    Adherent
  • Selection Marker
    Hygromycin B (100 μg/mL)
  • Culture Medium
    DMEM medium + 10% FBS
  • Freeze Medium
    10% DMSO + 90% FBS
  • Quantity
    1 vial contains at least 5x10^6 cells in 1 ml of 10% DMSO in FBS.
  • Storage
    Frozen in liquid nitrogen.
  • Mycoplasma Testing
    Negative
  • Sterility Testing
    Negative
  • Instructions for Use
    See data sheet for detailed culturing and assay protocol.
Receptor Assay
 ASGR1 FACS

Fig. FACS analysis of ASGR1 on HEK293/Human ASGR1 Stable Cell Line.
FACS assay shows that Anti-ASGR1 Antibody can bind to HEK293/Human ASGR1 Stable Cell Line. HEK293/Human ASGR1 Stable Cell Line was red line, Negative control HEK293 cells was grey line (QC tested).

Please contact us if you are interested in related cell pool service.

  • Background
    ASGPR, a transmembrane C-type lectin, recognizes a wide variety of ligands that contain either terminal galactose (Gal) or N-acetylgalactosamine (GalNAc) residues and has been identified as a highly selective receptor on hepatocytes. The ASGR is composed of both a major (ASGR1) and minor subunit (ASGR2). ASGR1 has been shown to be efficiently targeted to the plasma membrane and to undergo constitutive endocytosis and recycling and found mainly expressed in the human liver.
  • Limited Use&License Disclosure
    1. This cell line is provided for research use only. It is neither intended for any animal or human therapeutic use nor for any direct human in vivo use. You are restricted to share, modify, transfer, distribute, sell, sublicense, or otherwise make the cell line available for use to other researchers, laboratories, research institutions, hospitals, universities, or service organizations.
    2. ACROBIOSYSTEMS MAKES NO WARRANTIES OR REPRESENTATIONS OF ANY KIND, EITHER EXPRESSED OR IMPLIED, WITH RESPECT TO THE SUITABILITY OF THE CELL LINE FOR ANY PARTICULAR USE.
    3. ACROBIOSYSTEMS ACCEPTS NO LIABILITY IN CONNECTION WITH THE HANDLING OR USE OF THE CELL LINE.
    4. Modifications of the cell line, transfer to a third party, or commercial use of the cell line may require a separate license and additional fees. Please contact order@acrobiosystems.com for further details.
  • Clinical and Translational Updates

코멘트 (0)


재고상품 출발날짜: 영업일 기준 4일

가격(KRW) : 5,250,000

보급 및 전시



약물 개발 현황

  • Number of Launched Drugs:0 Details
  • Number of Drugs in Clinical Trials:0 Details
  • Latest Research Phase:Preclinical

Datasheet & Documentation

관련 제품

신제품

문의와 컨텐츠

This web search service is supported by Google Inc.

totop